Allosteric Modulators for Neuropathic Pain via CB1R G-Protein Bias
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain, such as tricyclic antidepressants and anticonvulsants, provide only partial relief and are associated with significant side effects, while opioid drugs are less effective and carry risks of addiction and tolerance, highlighting the need for new therapeutic targets, particularly functionally selective agonists for the cannabinoid type 1 receptor (CB1R) that minimize adverse effects.
Innovation Solution
Development of biased positive allosteric modulators (PAMs) of CB1R that enhance G protein signaling rather than β-arrestin recruitment, specifically designed compounds targeting the CB1R allosteric site to treat neuropathic pain with reduced psychoactive and hypothermic effects, exemplified by compounds of Formula I, which activate G-protein activation independently or in combination with orthosteric ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric CB1R agonists are used to treat neuropathic pain, then pain relief efficacy is improved, but psychoactive side effects and tolerance increase
Solution Approach 1:
The patent introduces an allosteric modulator as an intermediary substance that indirectly activates CB1R signaling through conformational changes rather than direct orthosteric binding. This mediator approach allows G protein-mediated analgesic effects to be achieved while avoiding the psychoactive side effects associated with direct orthosteric agonists like THC
Solution Approach 2:
The invention targets a specific local site on the CB1R receptor - the allosteric site distinct from the orthosteric binding pocket. By acting locally at this alternative site, the compound achieves functionally selective G protein activation without triggering the broader signaling pathways that lead to psychoactive effects
2Reliability
If broad CB1R activation is achieved through orthosteric agonists, then neuropathic pain relief is improved, but tolerance and addiction risks increase
Solution Approach 1:
The patent changes the binding parameter from orthosteric to allosteric site interaction, which fundamentally alters the activation mechanism. This parameter change results in functionally selective G protein coupling that does not trigger β-arrestin recruitment, thereby preventing tolerance and addiction mechanisms while maintaining analgesic efficacy
3Reliability
If functionally selective CB1R agonists are designed to enhance G protein signaling, then analgesic efficacy is improved, but selectivity and reduced side effects are difficult to achieve without structural information
Solution Approach 1:
The allosteric modulator serves as an intermediary that naturally provides functionally selective G protein activation without requiring complex rational design. The allosteric mechanism inherently couples to G proteins while excluding β-arrestin recruitment, simplifying the design process compared to orthosteric agonists
Data Source
AI summary
Provided are methods for treating neuropathic pain by administering to a subject in need thereof a compound comprising phenyl-indole scaffold, wherein the compound has a modulatory effect on cannabinoid type 1 receptor (CB1R). Pharmaceutical compositions containing compounds comprising phenyl-indole scaffolds and pharmaceutically acceptable carriers are also provided, along with methods of using the same.